NASDAQ:PLSE - Pulse Biosciences Stock Price, Forecast & News

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Pulse Biosciences Inc (NASDAQ:PLSE) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.57) EPS for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.04. View Pulse Biosciences' Earnings History.

Pulse Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Pulse Biosciences.

1 equities research analysts have issued 12-month target prices for Pulse Biosciences' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Pulse Biosciences' stock price to reach $6.00 in the next twelve months. This suggests that the stock has a possible downside of 12.4%. View Analyst Price Targets for Pulse Biosciences.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pulse Biosciences.

News stories about PLSE stock have been trending extremely negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pulse Biosciences earned a daily sentiment score of -4.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Pulse Biosciences.

Pulse Biosciences saw a drop in short interest in the month of February. As of February 14th, there was short interest totalling 2,330,000 shares, a drop of 5.3% from the January 30th total of 2,460,000 shares. Based on an average daily trading volume, of 49,800 shares, the short-interest ratio is presently 46.8 days. Approximately 21.0% of the company's shares are sold short. View Pulse Biosciences' Current Options Chain.

Some companies that are related to Pulse Biosciences include Antares Pharma (ATRS), SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), MiMedx Group (MDXG), Inovio Pharmaceuticals (INO), Alphatec (ATEC), OraSure Technologies (OSUR), Utah Medical Products (UTMD), Repro-Med Systems (REPR), Repro Med Systems (KRMD), Iradimed (IRMD), SeaSpine (SPNE), Accuray (ARAY) and Restoration Robotics (HAIR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Energous (WATT), Advanced Micro Devices (AMD), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), AbbVie (ABBV), Fate Therapeutics (FATE), Portola Pharmaceuticals (PTLA), Roku (ROKU) and Exelixis (EXEL).

(PLSE) raised $20 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.

Pulse Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (0.92%), Geode Capital Management LLC (0.75%), Griffin Asset Management Inc. (0.24%), Bank of New York Mellon Corp (0.15%), UBS Group AG (0.07%) and Barclays PLC (0.05%). View Institutional Ownership Trends for Pulse Biosciences.

PLSE stock was sold by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC. View Insider Buying and Selling for Pulse Biosciences.

PLSE stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State Street Corp, Barclays PLC, Geode Capital Management LLC, Griffin Asset Management Inc., UBS Group AG, Bank of New York Mellon Corp and Citigroup Inc.. View Insider Buying and Selling for Pulse Biosciences.

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PLSE stock can currently be purchased for approximately $6.85.

Pulse Biosciences has a market capitalization of $142.40 million. The company earns $-37,540,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Pulse Biosciences employs 54 workers across the globe.View Additional Information About Pulse Biosciences.

The official website for Pulse Biosciences is http://www.pulsebiosciences.com/.

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]